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The ATP sensitive P2X receptor family comprises seven
receptor subunits (P2X1–7) that assemble as homo- or
hetero-trimeric ion channels (North and Surprenant 2000).
They are a distinct class of ligand gated cation channels with
two transmembrane segments, intracellular amino and
carboxy termini and a large extracellular loop (Roberts et al.
2006). ATP is released into the extracellular space in a
variety of ways including vesicular release from neurons, in
response to shear stress, and following cell damage. P2X
receptors are involved in a range of processes including
neuronal excitability, pain sensation and bone formation
(Burnstock 2006). A consensus of key amino acids involved
in ATP action is emerging (Evans 2009). Positively charged
lysine residues 68, 70 and 309 (P2X1 receptor numbering)
seem likely to be involved in co-ordinating the binding of the
negatively charged phosphates of ATP (Ennion et al. 2000;
Jiang et al. 2000; Zemkova et al. 2007), and in addition
Lys308 in the P2X2 receptor (Lys309 P2X1 receptor
numbering) may contribute to channel gating (Cao et al.
2007). The AsnPheArg (290–292 P2X1 numbering) motif
has been suggested to be involved in agonist binding and
gating (Roberts and Evans 2007; Evans 2009). For P2X1
receptors an inter-subunit disulphide bond can form between
cysteine mutants K68C and F291C suggesting their close
proximity in the agonist binding site (Marquez-Klaka et al.
2007) and a similar ﬁnding has been reported for P2X2
receptors, in the case of the equivalent mutations in the P2X3
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Abstract
At the majority of mutants in the region Glu181-Val200
incorporating a conserved AsnPheThrFFxLys motif cysteine
substitution had no effect on sensitivity to ATP, partial agon-
ists, or methanethiosulfonate (MTS) compounds. For the
F185C mutant the efﬁcacy of partial agonists was reduced by
 90% but there was no effect on ATP potency or the actions
of MTS reagents. At T186C, F188C and K190C mutants ATP
potency and partial agonists responses were reduced. The
ATP sensitivity of the K190C mutant was rescued towards WT
levels by positively charged (2-aminoethyl)methanethiosulfo-
nate hydrobromide and reduced by negatively charged so-
dium (2-sulfonatoethyl) methanethiosulfonate. Both MTS
reagents decreased ATP potency at the T186C mutant, and
abolished responses at the F195C mutant.
32P-2-azido ATP
binding to the mutants T186C and K190C was sensitive to
MTS reagents consistent with an effect on binding, however
binding at F195C was unaffected indicating an effect on gat-
ing. The accessibility of the introduced cysteines was probed
with (2-aminoethyl)methanethiosulfonate hydrobromide-bio-
tin, this showed that the region Thr186-Ser192 is likely to form
a beta sheet and that accessibility is blocked by ATP. Taken
together these results suggest that Thr186, Phe188 and
Lys190 are involved in ATP binding to the receptor and
Phe185 and Phe195 contribute to agonist evoked conforma-
tional changes.
Keywords: agonist,ATP,binding,mutagenesis,P2Xreceptor.
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slightly larger (Marquez-Klaka et al. 2009).
A conserved region in the middle of the extracellular
loop incorporating a phenylalanine-threonine doublet
(Phe185Thr186 P2X1 receptor numbering) was also iden-
tiﬁed in P2X1 receptors that when mutated resulted in
decreased ATP potency and partial agonist action (Roberts
and Evans 2004, 2006). Recent studies on cysteine
mutants of the P2X2 and P2X4 receptors suggest that
ATP responses at the conserved threonine, but not the
phenylalanine of the doublet, can be modiﬁed by meth-
anethiosulfonate (MTS) reagents (Roberts et al. 2008).
Mutation of the nearby conserved lysine to alanine
(Lys190 in P2X1) resulted in an  5, 200 and 2000-
fold decrease in ATP potency at P2X1, P2X2 and P2X4
receptors respectively (Ennion et al. 2000; Jiang et al.
2000; Yan et al. 2005) suggesting this may also contribute
to agonist action. This region of the receptor contains a
high degree of amino acid conservation and for human
receptors in the twenty amino acid stretch Glu181-Val200
(P2X1 receptor numbering) ﬁve of them are totally
conserved and a further ﬁve show a conservative substi-
tution including the AsnPheThrFFxLys motif (Fig. 1).
Bioinformatic analysis predicts that part of this region
(Thr186-Ser192), incorporating residues that when mutated
have been shown to modify ATP sensitivity, forms a beta
sheet (Digby et al. 2005). Non-conserved residues also
play important roles in mediating the differences between
the properties of the P2X subunits and may have a
regulatory role in this region. However a systematic
analysis of the role of this region of the receptor, that
could substantiate the structural predictions, has not been
undertaken to date.
The substituted cysteine accessibility method has been
useful in probing the extracellular regions close to the
transmembrane segments and their contribution to ATP
action at the P2X receptor (Jiang et al. 2000; Roberts and
Evans 2007). In this study we have used cysteine substi-
tution mutagenesis of the region Glu181-Val200 of the
P2X1 receptor to (i) determine the effects of cysteine
substitution on ATP sensitivity and the efﬁcacy of partial
agonists, (ii) establish whether charged cysteine reactive
MTS reagents modify ATP responses, (iii) address whether
mutations and MTS compounds result in an effect on
agonist binding or channel gating using a 2-azido ATP
binding assay, and (iv) utilized an (2-aminoethyl)methan-
ethiosulfonate hydrobromide (MTSEA)-biotinylation assay
to measure the accessibility of introduced cysteine residues,
and whether this is sensitive to receptor activation. These
studies provide a novel insight into the structural organi-
zation and properties of this region of the receptor.
Methods
Site-directed mutagenesis
Cysteine point mutations for residues Glu181–Val200 were intro-
duced via the QuikChange
TM mutagenesis kit (Stratagene, La Jolla,
CA, USA) using a human P2X1 receptor plasmid as the template as
described previously (Ennion et al. 2000). Production of the correct
mutations and absence of coding errors in the P2X1 mutant
constructs was veriﬁed by DNA sequencing (Automated ABI
Sequencing Service, University of Leicester).
Expression in Xenopus laevis oocytes
Wild type and mutant constructs were transcribed to produce
sense strand cRNA (mMessage mMachine
TM, Ambion, Austin,
P2X1 EAENFTLFIKNSISFPRFKV
P2X2 MAPNFTILIKNSIHYPKFHF
P2X3 EAENFTIFIKNSIRFPLFNF
P2X4 AAENFTLLVKNNIWYPKFNF
P2X5 EAEDFTIFIKNHIRFPKFNF
P2X6 QAQNFTLFIKNTVTFSKFNF
P2X7 SAENFTVLIKNNIDFPGHNY
Schi MVYNYTLLIKNDINFEKGGI
Alga  NVGNFTVFTRISVEFPGIPD
Dict DIESFTILIDHTMYAPSLGI
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Fig. 1 Effects of cysteine point mutants of E181 to V200C on ATP
potency at human P2X1 receptors. (a) Sequence line-up for the region
corresponding to E181 to V200 of the P2X1 receptor for the seven
human, Schistosoma mansoni (Schi) (Agboh et al. 2004), the green
alga Ostreococcus tauri (Alga) (Fountain et al. 2008) and amoeba
Dictyostelium discoidium (Dict) (Fountain et al. 2007) P2X receptors.
Residues conserved in at least ﬁve of the human isoforms are shown
in black bold, conservative substitutions are shown underlined in bold
gray. (b) Concentration responses to ATP for oocytes expressing WT,
T186C, F188C and K190C mutant P2X1 receptors. Application of ATP
is indicated by bar. (c) Summary of concentration response data for
WT and mutants T186C, F188C and K190C that showed signiﬁcant
decreases in ATP potency (n = 3–4).
  2009 The Authors
Journal Compilation   2009 International Society for Neurochemistry, J. Neurochem. (2009) 109, 1042–1052
Cysteine mutagenesis of P2X receptors | 1043TX, USA) as described previously (Ennion et al. 2000). Manually
defolliculated stage V Xenopus laevis oocytes were injected with
50 nL (50 ng) of cRNA using an Inject + Matic microinjector
(J. Alejandro Gaby, Gene ´va, Switzerland) and stored at 18 Ci n
ND96 buffer (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2,1m M
MgCl2, 5 mM sodium pyruvate, 5 mM HEPES, pH 7.6). Media
was changed daily prior to recording 3–7 days later.
Electrophysiological recordings
Two-electrode voltage clamp recordings (at a holding potential of
)60 mV) were carried out on cRNA injected oocytes using a
GeneClamp 500B ampliﬁer with a Digidata 1322 analog-to-digital
converter and pClamp 8.2 acquisition software (Axon Instruments,
Molecular Devices, Foster City, CA, USA) as previously described
(Ennion et al. 2000). Native oocyte calcium activated chloride
currents in response to P2X receptor stimulation were reduced by
replacing 1.8 mM CaCl2 with 1.8 mM BaCl2 in the ND96 bath
solution. ATP (Mg salt) was applied via a U-tube perfusion system
as was 2¢,3¢-O-(4-benzoyl)-ATP (BzATP) and P
1,P
5-diadenosine
5¢-pentaphosphate (Ap5A) (all from Sigma, Poole, UK). ATP was
applied at 5-min intervals. Using this regime reproducible ATP
evoked responses were recorded. Individual normalized concen-
tration response curves were ﬁtted with the Hill equation:
Y =[ ( X)
H/[(X)
H + (EC50)
H] where Y is response, X is agonist
concentration, H is the Hill coefﬁcient, and EC50 is the
concentration of agonist evoking 50% of the maximum response.
pEC50 is the –log10 of the EC50 value. For the calculation of EC50s
individual concentration response curves were generated for each
experiment and statistical analysis carried out on the pEC50 data
generated. In the ﬁgures concentration response curves are ﬁtted to
the mean normalized data.
Characterisation of the effects of methanethiosulfonate
compounds
To study the effect of MTS compounds on ATP activation at wild
type and cysteine mutants, ATP ( EC50 concentration) was
applied and either MTSEA or sodium (2-sulfonatoethyl) methan-
ethiosulfonate (MTSES) (Toronto Research Chemicals, Toronto,
Canada) were bath-perfused (for at least 5 min; the recovery time
required between application to see reproducible responses) prior
to application of ATP via the U-tube. MTS reagents (1 mM) were
prepared immediately before use. The effect of MTS reagents on
the concentration responses to ATP were investigated following 1-
h incubation with MTSEA (1 mM) or 3-h incubation with
MTSES (1 mM) to irreversibly modify all the P2X receptors,
following washout of MTS reagents ATP was applied via the U-
tube with ND96 bathing solution (no MTS reagents present). We
have previously shown that concentration response curves
generated with MTS reagents in the bath or after longer term
treatment followed by washout of the MTS reagents give the
same results for a range of P2X1 receptor cysteine mutants
(Roberts and Evans 2007).
32P-2-azido ATP radiolabelling of the P2X1 receptor
To assess any effects of MTS reagents on agonist binding we used a
32P-2-azido ATP binding assay as described previously (Roberts
et al. 2008). We used this for wild type (WT), T186C, K190C and
F195C mutants. Densitometry analysis was carried out on the
resultant ﬁlms with data corrected by background subtraction
calculated for each lane and expressed as percentage of control for
WT or a particular mutant.
Western blotting
(2-Aminoethyl)methanethiosulfonate hydrobromide biotin was used
to probe the various cysteine mutants to map the extracellular region
E181-V200 of the P2X1 receptor as described previously (Roberts
et al. 2008). MTSEA biotin reacts covalently with sulfhydryl groups
provided by accessible cysteine residues. The wild type P2X1
receptor contains no ‘free’ cysteine residues (Ennion and Evans
2002) and therefore an introduced cysteine would be free to bind
MTS compounds if accessible.
Analysis
All data are shown as mean ± standard error of the mean. Signiﬁcant
differences between WT and mutants were calculated by one way
analysis of variance followed by Dunnett’s test for comparisons of
individualmutantsagainstcontrolusingGraphpadPrism5(GraphPad
SoftwareInc.,SanDiego,CA,USA).Thesigniﬁcanceofanychanges
in ATP potency by MTS compounds, and the effects of ATP on
MTSEA-biotinylation at particular mutants were determined with the
appropriate Student’s t-test. n corresponds to the number of oocytes
tested for electrophysiological data, and for biochemical studies
experiments were repeated at least three times.
Results
Effects of cysteine substitution on agonist action
At WT P2X1 receptors ATP evoked concentration dependent
desensitizing inward currents with an EC50 of  0.8 lMa s
reported previously (Roberts and Evans 2005). There were
no signiﬁcant differences in the amplitude of peak inward
currents evoked by a maximal concentration of ATP between
WT and any of the mutants E181C to V200C (Table 1). For
the majority of the mutants in addition there was no effect on
ATP sensitivity. This conﬁrms previous studies on alanine
mutants of residues Glu183, Asn184, Asn191, Pro196 and
Phe198 (Jiang et al. 2000; Ennion et al. 2001; Roberts and
Evans 2004, 2005, 2006). The P2X1 receptor F185C mutant
had no effect on ATP potency similar to an alanine mutation
at the equivalent position in the Dictyostelium P2X receptor
(Fountain et al. 2007), but contrasts with a previous P2X1
receptor mutant F185A that had a 10-fold decrease in
potency (Roberts and Evans 2004), and the 3 and 20-fold
decreases in potency for the equivalent mutants at P2X2 and
P2X4 receptors (Zemkova et al. 2007; Roberts et al. 2008).
There were signiﬁcant decreases in ATP EC50 to 6.5, 5.8 and
3.4 lM for the mutants T186C, F188C and K190C respec-
tively and also a slowing in the time-course of desensitization
of the current (823 ± 160, 1720 ± 233, 2392 ± 246 and
1720 ± 213 ms for the 50% decay time for the ATP evoked
current for WT and mutants respectively, p < 0.001 for the
mutants compared to WT, n = 7–11, Fig. 1). This pattern of
Journal Compilation   2009 International Society for Neurochemistry, J. Neurochem. (2009) 109, 1042–1052
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consistent with the beta sheet prediction for this region of the
receptor (Digby et al. 2005) (that is substantiated by the
biotinylation studies – see later) that could face the ATP
binding pocket. In addition the Hill slope of the T186C
mutant was signiﬁcantly increased almost threefold to
2.95 ± 0.07 (Table 1).
At WT receptors the partial agonists Ap5A and BzATP
have an efﬁcacy of 0.45–0.50 as described previously
(Roberts and Evans 2004). At the majority of mutants, like
for sensitivity to ATP, there was no change in the efﬁcacy of
the partial agonists (Fig. 2). For two mutants, F185C and
R197C that had no change in ATP potency the partial agonist
responses were reduced, at F185C both BzATP and Ap5A
efﬁcacy was 0.03 and at R197C responses were reduced to 
0.13 for the two agonists. At the mutants T186C, F188C and
K190C, with a decrease in ATP potency there was also a
signiﬁcant decrease in the efﬁcacy of the partial agonists
(Fig. 2), this was greatest for the T186C mutant (efﬁ-
cacy < 0.01). At WT P2X1 receptors the pEC50 for Ap5A
was 6.2 ± 0.5, this was unaffected for R197C (5.92 ± 0.23,
p = 0.23) but sensitivity to Ap5A was reduced for both
F188C and K190C mutants (pEC50 5.33 ± 0.16 and
5.70 ± 0.07 respectively, p < 0.001 for both, n = 3) (the
responses were too small to study partial agonists sensitivity
at F185C and T186C mutants). The sensitivity to BzATP was
also reduced compared to WT (pEC50 6.52 ± 0.1) for the
mutants F188C and R197C (pEC50s 5.40 ± 0.06 and
5.52 ± 0.01 respectively, p < 0.001 for both, n = 3, the
responses were too small to study the partial agonist
sensitivity of BzATP at K190C).
Effects of MTS reagents at cysteine mutants
Methanethiosulfonate reagents have been used to modify
accessible cysteine residues and in investigating the site of
agonist action at P2X receptors (Jiang et al. 2000; Roberts
Table 1 Effects of cysteine substitution on peak response and ATP
action
Peak current (nA) ATP pEC50 Hill
WT 9725 ± 621 6.10 ± 0.07 1.01 ± 0.05
E181C 9509 ± 1014 5.94 ± 0.17 0.73 ± 0.05
A182C 11 874 ± 853 5.75 ± 0.11 1.25 ± 0.31
E183C 11 422 ± 1030 5.67 ± 0.23 0.88 ± 0.20
N184C 10 729 ± 900 6.18 ± 0.11 0.88 ± 0.04
F185C 12 561 ± 1506 5.76 ± 0.13 1.33 ± 0.06
T186C 8065 ± 1286 5.19 ± 0.06*** 2.95 ± 0.07***
L187C 11 730 ± 877 5.76 ± 0.12 1.11 ± 0.08
F188C 9799 ± 662 5.25 ± 0.09*** 1.26 ± 0.06
I189C 10 578 ± 655 5.81 ± 0.19 0.86 ± 0.07
K190C 8411 ± 745 5.45 ± 0.08* 1.15 ± 0.03
N191C 7048 ± 538 6.01 ± 0.03 1.04 ± 0.08
S192C 9553 ± 519 5.88 ± 0.10 0.92 ± 0.06
I193C 7573 ± 663 6.00 ± 0.14 1.02 ± 0.10
S194C 9159 ± 813 6.21 ± 0.06 0.93 ± 0.13
F195C 7551 ± 647 6.14 ± 0.15 0.82 ± 0.10
P196C 10 056 ± 704 6.02 ± 0.07 1.14 ± 0.05
R197C 8268 ± 1081 5.96 ± 0.13 1.04 ± 0.20
F198C 8586 ± 816 6.10 ± 0.24 0.85 ± 0.12
K199C 8926 ± 825 6.10 ± 0.12 1.03 ± 0.16
V200C 10 426 ± 1004 5.99 ± 0.09 0.87 ± 0.86
Peak current values taken on the ﬁrst application of a maximal con-
centration of ATP (100 lM). pEC50 values shown as calculated from
ﬁts of individual concentration response curves. pEC50 is –log10 of the
EC50 for ATP. Hill coefﬁcient of ﬁtted curves is shown. Signiﬁcant
differences from WT P2X1 receptors are indicated *p < 0.01 and
***p < 0.001, n = 8–27 for peak currents, n = 3–4 for pEC50.
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Fig. 2 Efﬁcacy of the partial agonists Ap5A and BzATP. (a) Currents
evoked by ATP and Ap5A application (both 100 lM) at WT, F185C,
T186C and K190C mutant P2X1 receptors. Agonist application for 3 s
is indicated by bar. (b) Summary of the efﬁcacy of the partial agonist
Ap5A (100 lM) expressed as a percentage of the response to a
maximal concentration of ATP (100 lM). (c) Summary of the efﬁcacy
of the partial agonist BzATP (100 lM) expressed as a percentage of
the response to a maximal concentration of ATP (100 lM). Signiﬁcant
reductions in efﬁcacy are shown as black bars, *p < 0.05, **p < 0.01,
***p < 0.001, (n = 3–5).
  2009 The Authors
Journal Compilation   2009 International Society for Neurochemistry, J. Neurochem. (2009) 109, 1042–1052
Cysteine mutagenesis of P2X receptors | 1045and Evans 2007; Roberts et al. 2008). Charged MTS
reagents have been particularly useful as the ATP molecule
has a negatively charged phosphate tail, and under physio-
logical conditions magnesium is complexed with ATP giving
rise to localized positive charge associated with the agonist.
We have therefore determined whether ATP evoked
responses at mutant receptors can be modiﬁed by positively
charged MTSEA and negatively charged MTSES. An EC50
concentration of ATP was used to test the effects of MTS
reagents as this would show the greatest sensitivity to any
modiﬁcation. Positively charged MTSEA (1 mM) potenti-
ated the amplitude of responses at WT P2X1 receptors by
24.4 ± 6.1%, similar to that described previously for WT
P2X1 receptors (Roberts and Evans 2007). For sixteen of
the mutants there was no signiﬁcant difference in the effects
of MTSEA (Fig. 3). Responses were increased by 93.7 ±
19.6% and 73.0 ± 11.9% for K190C and R197C mutants and
inhibited by 76.4 ± 4.6% and 73.0 ± 11.9% for T186C and
F195C mutants respectively. The maximal effects of the
MTSEA were generally observed on the ﬁrst application of
ATP following 5-min treatment with MTSEA.
Following washout of MTSEA WT responses returned to
control values (0.5 ± 7.4% change from control). For R197C
the effects of MTSEAwere immediately reversed on washout
(to 2 ± 6.7% change from control) this suggests that the
effects of MTSEA at R197C do not result from the
irreversible modiﬁcation of the introduced cysteine residue.
The inhibitory effects of MTSEA at T186C and F195C were
still signiﬁcant following 5-min washout of MTSEA how-
ever the level was reduced to 44.8 ± 7.2% and 36.2 ± 6.7%
respectively. Similarly for K190C the potentiatory effect of
MTSEA was maintained albeit at a reduced level following
washout of MTSEA (28.6 ± 8.4% potentiation). Trafﬁcking
of new P2X1 receptors from the intracellular space that have
not been modiﬁed by MTSEA could account for this partial
reversal and a similar phenomenon was seen for cysteine
mutants of the P2X4 receptor (Roberts et al. 2008). We
previously showed that 1-h pre-incubation followed by
washing with membrane permeant MTSEA was sufﬁcient
to modify the pool of P2X4 receptors and overcome the
apparent reversibility of the effect (Roberts et al. 2008).
Following 1-h pre-treatment with MTSEA followed by
washing the peak amplitude of WT currents was unaffected
(6.6 ± 8.3% change compared to control). In contrast T186C
and F195C mutants were reduced by 80.5 ± 6.2% and
91.7 ± 2.2% compared to control following pre-treatment
consistent with that seen with MTSEA in the bath and
indicative of an irreversible modiﬁcation. Responses of
K190C to 1 lM ATP were potentiated by 220 ± 28% by 1-h
pre-treatment with MTSEA consistent with an irreversible
modiﬁcation of the introduced cysteine residue. R197C
mutants were unaffected by pre-treatment showing that this
mutant is not irreversibly modiﬁed by MTSEA and the
reversal of responses on washout of MTSEA does not result
from rapid trafﬁcking of unmodiﬁed receptors to the cell
surface. These results demonstrate that P2X1 receptors are
likely to undergo constitutive trafﬁcking in oocytes and
partial washout of MTSEA effects at T186C, F195C and
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Fig. 3 Effects of charged MTS reagents on ATP evoked P2X1
receptor currents. (a) Responses to an  EC50 concentration of ATP
are shown before (open symbol) and after the application of 1 mM
MTSEA (ﬁlled symbol) for the mutants F185C, T186C and K190C.
ATP application (3 s) is indicated by bar. (b) Summary of the effects
of MTSEA on WT and mutant P2X1 receptors. (c) Responses to an
 EC50 concentration of ATP are shown before (open symbol) and
after the application of 1 mM MTSES (ﬁlled symbol) for the mutants
F185C, T186C and K190C. ATP application (3 s) is indicated by bar.
(d) Summary of the effects of MTSES on WT and mutant P2X1
receptors. Data are expressed as % change (0% indicates no
change), on MTS application, signiﬁcant differences from WT are
shown by black bars, *p < 0.05, ***p < 0.001, (n = 3–14).
Journal Compilation   2009 International Society for Neurochemistry, J. Neurochem. (2009) 109, 1042–1052
  2009 The Authors
1046 | J. A. Roberts et al.K190C mutants is likely to result from trafﬁcking of un-
modiﬁed receptors to the cell surface. Longer incubation with
MTSEA allows modiﬁcation of the whole pool of P2X
receptors and results in irreversible modiﬁcation of T186C,
F195C and K190C mutants with no effect on WT or R197C
mutant receptors. This is consistent with previous studies on
P2X1 receptor cysteine mutants where the effects of MTS
reagents on ATP concentration response curves were the
same whether the MTS was applied with ATP or in the
absence of MTS reagents following long term exposure to
irreversibly modify the whole pool of introduced cysteine
residues (Roberts and Evans 2007).
Negatively charged MTSES (1 mM) had no effect on WT
P2X1 receptor currents in response to an EC50 concentration
of ATP similar to that reported previously (Roberts and
Evans 2007). For 16 of the mutants there was no signiﬁcant
effect compared to WT (Fig. 3). At R197C responses were
potentiated by  70% however they returned to control
following washout ()6 ± 4.9%) and it seems that like the
response to MTSEA results from a reversible effect on the
channel. For T186C, K190C and F195C ATP evoked
currents were reduced by 80–95%, and following 5-min
washout of MTSES they were still inhibited signiﬁcantly by
45–55%. This once again suggests that new unmodiﬁed
receptors are being trafﬁcked to the cell surface during the
washout. We have previously shown that a 3-h incubation
with membrane impermeant MTSES is sufﬁcient to irrevers-
ibly modify the total pool of P2X4 receptors (Roberts et al.
2008). When oocytes expressing these P2X1 receptor
mutants were pre-treated with MTSES for 3 h, followed by
washout, a similar level of inhibition was seen as for bath
application, indicating that the partial reversal results from
constitutive trafﬁcking of un-modiﬁed receptors to the cell
surface (and complete turnover of the receptor pool occurs
within 3 h).
Effects of MTS reagents on ATP potency and agonist
binding
The mutants T186C and F195C were inhibited by both
MTSEA and MTSES whereas at the K190C mutant the
effects of the MTS reagents were dependent on the charge,
with potentiation by positively charged MTSEA and inhibi-
tion by negatively charged MTSES. To determine whether
the MTS reagents had an effect on ATP potency and/or the
amplitude of maximal responses we constructed concentra-
tion response curves following MTS treatment (1 h MTSEA
or 3 h MTSES followed by washing) to irreversibly modify
free cysteine residues (Fig. 4). At the T186C mutant MTSEA
and MTSES treatment decreased ATP potency  10 and 5-
fold (p < 0.005) with no effect on the maximal response. In
addition the Hill slope was reduced back to normal WT
levels on treatment with the MTS reagents however the
mechanism associated with this is unclear. At the K190C
mutant ATP potency was increased  3-fold by MTSEA
(p < 0.05) with no effect on the maximal response whilst
MTSEA decreased ATP potency threefold (p < 0.001) and
the maximal response by 35% (p < 0.01). At the F195C
mutant ATP responses to 1 mM ATP were reduced by > 90%
by both MTSEA and MTSES (p < 0.001).
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Fig. 4 Effects of MTS reagents on ATP concentration responses at
P2X1 receptor mutants. Concentration response curves to ATP were
determined under control conditions or following incubation with
MTSEA (1 mM for 1 h followed by washout) or MTSES (1 mM for 3 h
followed by washout). (a) At T186C the EC50 was signiﬁcantly
increased by both MTSEA and MTSES with no effect on the peak
response. (b) At K190C MTSEA signiﬁcantly increased whilst MTSES
signiﬁcantly decreased ATP potency. For MTSES peak current
responses were also reduced. (c) MTSEA and MTSES treatment re-
duced responses at the F195C mutant receptor by > 90% even for a
maximal concentration of ATP (1 mM).
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response curves for T186C, K190C and F195C could result
from an effect on the binding of ATP to the receptor and/or
the subsequent conformational change associated with
gating of the ionic pore. Radiolabelled 2-azido ATP cross-
linking can be used to measure binding to P2X1 receptors
(Roberts and Evans 2007; Agboh et al. 2009). In this study,
we have tested whether 2-azido ATP binding to WT and
mutant P2X1 receptors is sensitive to modiﬁcation by MTS
reagents (Fig. 5).
32P-2-azido ATP cross-linking to the WT
P2X1 receptor was unaffected by MTSEA or MTSES
treatment consistent with the little or no effect of these
compounds on ATP evoked responses. At the T186C
mutant 2-azido ATP cross-linking under control conditions
was reduced by 33 ± 4% compared to WT (p < 0.01)
consistent with the decrease in ATP potency. 2-azido ATP
cross-linking was further reduced by both MTSEA
(p < 0.001) and MTSES (p < 0.05) and mirrored their
inhibitory effects on ATP evoked currents. At K190C there
was no change in 2-azido ATP binding compared to
control. There was a trend towards an increase in 2-azido
ATP binding consistent with the increase in ATP potency
following MTSEA application however this did not reach
signiﬁcance. The lack of signiﬁcance may reﬂect that small
changes in ATP potency (threefold) are on the threshold of
sensitivity that can be detected in the binding assay.
However MTSES reduced 2-azido ATP cross-linking at
K190C by  80% (p < 0.001) consistent with the rightward
shift in agonist sensitivity and a depression of the maximal
response to ATP. These effects at T186C and K190C are
indicative of an effect of MTS reagents on agonist binding.
For the F195C mutant MTSEA or MTSES had no effect on
the cross-linking of 2-azido ATP even though these MTS
reagents essentially abolished ATP evoked responses. This
shows that the MTS reagents do not affect agonist binding
but inhibit the gating of the F195C mutant channel. Overall
these results suggest that the
32P-2-azido ATP cross-linking
assay can be used to differentiate effects of the MTS
reagents on agonist binding or the subsequent gating of the
channel.
Conformational dependent accessibility of cysteine
mutants
Bioinformatic predictions suggest that part of Glu181-Val200
region may form a beta sheet however there is no direct
evidence to verify this, or to suggest whether this portion of
the receptor is accessible at the receptor surface. We have
therefore used an MTSEA-biotinylation assay to map the
surface accessibility of the cysteine substituted region and to
determine whether it is sensitive to the activation state
(Roberts and Evans 2007) (Fig. 6). No MTSEA-biotinylation
was detected for WT P2X1 receptors either under resting
conditions (in the presence of apyrase to break down any
ATP released from the oocytes) or following ATP application
as reported previously (Roberts and Evans 2007) and
consistent with the ten cysteine residues in the extracellular
domain forming ﬁve disulphide bonds (Ennion and Evans
2002). MTSEA-biotinylation was below the threshold for
detection for the mutants E181C, E183C, L187C, I189C,
N191C and I193C indicating that these introduced cysteine
residues are buried within the protein and inaccessible. Weak
biotinylation was seen for the N184C and S194C mutants. At
A182C, F185C, T186C, F188C, K190C, S192C and F195C
mutants robust MTSEA-biotinylation was seen with apyrase
and this was reduced or abolished following ATP pre-
treatment suggesting that the accessibility of these residues is
blocked either directly by ATP binding or as a result of a
conformational change in the receptor. MTSEA-biotinylation
was detected for P196C-V200C mutants in the presence of
apyrase or ATP indicating that these residues are accessible
in either the resting or activated conformation of the P2X1
receptor. The pattern of biotinylation between Thr186 and
Ser194 with alternative residues being biotinylated is con-
sistent with a beta sheet and substantiates bioinformatic
predictions.
Discussion
In this study, we used cysteine scanning mutagenesis of
Glu181 to Val200 to provide an unbiased insight into the
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Fig. 5 Effects of MTS reagents on
32P-2-azido ATP cross-linking to
WT and mutant P2X1 receptors. (a) Oocytes expressing WT and
mutant P2X1 receptors were UV irradiated in the presence of
32P-2-
azido ATP and P2X1 receptors were isolated by immunoprecipitation
and run on a gel and exposed to X-ray ﬁlm. The autoradiographs show
the level of radioactivity associated with the P2X1 receptors under
control conditions and the effects of MTSEA or MTSES (both 1 mM).
(b) Summary data of the effects of MTSEA and MTSES on 2-azido
ATP cross-linking to WT, T186C, K190C and F195C mutant P2X1
receptors. Data are expressed as % of control condition for each group
of oocytes and corrected for background levels. (n = 4 batches of
oocytes for each). **p < 0.05, ***p < 0.001.
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1048 | J. A. Roberts et al.contribution of this region to P2X1 receptor properties. The
majority of the mutants had no effect on either ATP potency
or MTS reagent action and can be discounted as essential
for normal receptor function and aid in the reﬁnement of
models of residues important in mediating ATP action. The
study highlights a signiﬁcant contribution of residues
Phe185, Thr186, Phe188, Lys190 and Phe195 in mediating
the actions of ATP and gives insight into the surface
accessibility and conformational changes in the receptor on
activation.
The Phe185Thr186 doublet is conserved throughout the
P2X receptor family (the exception being a conservative
substitution of a tyrosine for phenylalanine in the Schisto-
some P2X receptor) (Agboh et al. 2004). The lack of effect
of MTS reagents at the F185C mutant even though they are
accessible to MTSEA-biotinylation conﬁrms and extends
previous studies on P2X2 and P2X4 receptors (Roberts et al.
2008) and suggest that this residue does not face directly into
the ATP binding pocket. However the reduction in partial
agonist responses for the F185C mutant suggests that this
may result from a localized effect on the adjacent threonine
residue. The mutation T186C at the P2X1 receptor gave a
modest  8-fold decrease in ATP potency similar to that for
the T186A mutant and equivalent cysteine mutants at P2X2
and P2X4 receptors (Roberts et al. 2008) in addition the
partial agonist actions of BzATP and Ap5A were essentially
abolished. We used 2-azido ATP binding to address directly
whether changes in agonist potency result from an effect on
the initial binding step (that may involve conformational
change) or the subsequent activation of the channel (gating).
At the T186C mutant ATP potency and 2-azido ATP binding
was reduced under control conditions compared to WT and
ATP sensitivity and 2-azido ATP binding was further reduced
by the MTS reagents. In contrast at F195C agonist action was
reduced by MTS reagents with no effect on 2-azido ATP.
These results suggest that the 2-azido ATP assay can be used
to discriminate mutations and treatment that acts on the
agonist binding step (T186C) from effects on the subsequent
opening of the channel (F195C). The sensitivity of the
T186C mutant to MTS reagents was independent of
the charge and appeared to result from the bulk of the
substitution like that reported for the P2X4 receptor (Roberts
et al. 2008). This suggests that this residue is not involved in
coordination of the charged phosphates of ATP and is likely
to be involved in binding of the adenine or ribose groups.
The ATP sensitivity of the K190C mutant showed a
modest 3–4 fold decrease compared to WT channels. ATP
potency was increased back to WT levels by treatment with
positively charged MTSEA and inhibited by negatively
charged MTSES demonstrating the contribution of charge at
this position to agonist action. This is the same as the charge
dependence of MTS reagent effects at the cysteine mutants of
the conserved lysine residues implicated in ATP binding at
the receptor (Roberts and Evans 2007; Roberts et al. 2008).
Lys190 is conserved in all the human P2X receptors as well
as the Schistosome P2X (Agboh et al. 2004) with a
conservative Arg substitution at the Algal P2X receptor
(Fountain et al. 2008). Interestingly the equivalent residue in
the Dictyostelium P2X receptor is a negatively charged
aspartate (Fountain and North 2006). The reduction in ATP
sensitivity on MTSES treatment at the K190C mimics this
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N191C
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Fig. 6 MTSEA-biotinylation reveals the surface accessibility of the
region E181-V200. Representative western blots show the equivalent
total levels of WT and P2X1 receptor mutants expressed in the oo-
cytes used for the biotinylation assay (left hand panel). To determine
the surface accessibility of introduced cysteine residues oocytes were
incubated with MTSEA-biotin, and biotinylated proteins isolated, run
on a gel and blotted with an anti-P2X1 receptor antibody. Oocytes
were either pre-treated with apyrase (to break down any endogenous
nucleotides) or ATP (to activate the receptor). For WT receptors no
biotinylation could be detected. Biotinylation was also below the limit of
detection for E181C, E183C, L187C, I189C, N191C and I193C. At
N184C and S194C weak biotinylation that was ATP sensitive was
recorded. ATP sensitive biotinylation was detected at A182C, F185C,
T186C, F188C, K190C, S192C and F195C. MTSEA-biotin was
observed for P196C-V200C mutants either in the absence of presence
of ATP. Blots are representative of those from three to eight separate
batches of oocytes.
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that the reduced ATP potency at the Dictyostelium receptor
may result in part from this charge difference. The
reduction in 2-azido ATP cross-linking at K190C by
MTSES, and decreased efﬁcacy of the partial agonists
suggests that the change in potency results from a decrease
in agonist binding. The modest effects of the Lys190
mutation suggest that this residue may function to ﬁne tune
agonist sensitivity at P2X1 receptors and this residue is not
as important in mediating the action of ATP as conserved
Lys68 and Lys308. However more dramatic decreases in
potency have been reported for the alanine mutations of the
equivalent lysine residues at P2X2 and P2X4 receptors
(200 and 2000-fold respectively) (Ennion et al. 2000; Jiang
et al. 2000; Yan et al. 2005) indicating that at these
receptors the lysine makes a greater contribution. This
could be as in these receptors the lysine is perhaps closer
to the binding pocket. This is supported by recent studies
from P2X2–4 receptors suggesting that there may be some
differences in the dimensions of the ATP binding pocket
between receptor subunits (Marquez-Klaka et al. 2009).
Alternatively the conserved lysine could play a subtype
dependent role in interactions with other charged residues
in the extracellular loop.
An aromatic residue is conserved at position 195 (P2X1
receptor numbering) throughout the mammalian, Schisto-
some and Algal P2X receptors and in the Dictyostelium
receptors there is an adjacent tyrosine residue. Responses
were essentially abolished by treatment of F195C mutants
with MTS reagents (even to a supra-maximal concentration
of ATP) and following MTS treatment the level of azido-ATP
binding was unaffected. This demonstrates that the reduction
in response at F195C does not result from a decrease in
agonist binding to the receptor but from an effect on either
gating and/or ionic permeation. The reduction in MTSEA-
biotinylation at the F195C mutant in response to ATP
demonstrates a conformation change in the receptor on
activation rendering the position inaccessible. One interpre-
tation of these results is that the incorporation of the MTS
reagents inhibits the conformational change so stopping
gating of the channel. Interestingly the adjacent region
Pro196 to Val200 can be MTSEA-biotinylated (and R197C
shows a decrease in partial agonist action suggesting that this
region may have some minor effect on channel properties).
However, the sensitivity of Pro196 to Val200 to MTSEA-
biotinylation this is unaffected by ATP application, suggest-
ing that Phe195 could act as a pivot around which
conformational changes occur.
The results from the present study show that the region
Phe185-Phe195 plays an important role in channel regula-
tion. In the stretch Thr186-Ser192 alternative residues were
MTSEA-biotinylated. This is consistent with bioinformatic
predictions that this region of the receptor forms a beta sheet
(Digby et al. 2005). Similarly Thr186, Phe188 and Lys190
mutants showed decreases in ATP potency and partial agonist
action consistent with a beta sheet. The lack of effect of
MTSEA or MTSES at F188C suggests that this residue does
not make as close contact to the ATP molecule as Thr186 and
Lys190. We therefore tested the larger MTS reagent [2-
(Trimethylammonium) ethyl] methanethiosulfonate Bro-
mide) (MTSET). MTSET (1 mM) had little or no effect on
WT P2X1 receptor mediated currents (115 ± 6.5% of
control). At the F188C mutant MTSET (1 mM) reduced
the response to an EC50 concentration of ATP (5 lM) by
76.6 ± 6.6% (p < 0.001, n = 4). This reduction in amplitude
was also accompanied with a slowing in the time-course of
the ATP current consistent with a reduction in agonist
potency and consistent with a contribution to the agonist
binding pocket. Taken together these results suggest that
Thr186, Phe188 and Lys190 face the ATP binding pocket.
The biotinylation of the face of the beta sheet was also
sensitive to the application of ATP indicating that the
accessibility of the beta sheet is either blocked by ATP
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Fig. 7 Model of the ATP binding site. Portions of the extracellular loop
adjacent to either the ﬁrst (in gray) or second (in black) transmem-
brane segment are shown for two adjacent P2X1 receptor subunits.
Conserved residues that have been shown to contribute to ATP po-
tency are shown (gray residues correspond to conserved aromatic
residues in areas of high conservation). The dotted line corresponds to
the region Glu181-Val200 that was characterized in the present study,
the zig-zag line corresponds to the region of beta sheet as indicated by
the pattern of MTSEA-biotinylation. Based on studies on the zinc and
copper binding site of P2X7 receptors (Liu et al. 2007) it is possible
that residues His62 and Asp197 (P2X7 receptor numbering, indicated
by black balls) are close together (shown by arrow) as suggested for
residues involved in the zinc binding site at P2X2 receptors (Nagaya
et al. 2005). This would bring the residues Phe195, Lys190 and
Thr186 close to the putative ATP binding site. If this is the case Lys190
could be close to the other conserved lysine residues and this could
account for the charge dependent effects of MTS reagents on the
K190C mutant. Asn184 is glycosylated (Roberts and Evans 2006).
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agonist binding pocket. At either end of the beta sheet are
conserved phenylalanine residues that we have suggested
contribute to conformational changes (through effects on
partial agonists F185C or MTS action F195C) in response to
agonist action.
The region Phe185-Phe195 is in the middle of the
extracellular loop sequence  95–116 residues from others
suggested to be in the ATP binding pocket. A model for
P2X1,2&4 receptors suggests that the lysines Lys68,70&309
along with Asn290Phe291Arg292 (P2X1 receptor number-
ing) co-ordinate ATP binding (Roberts et al. 2008) and the
phenylalanine residue is close to the ﬁrst lysine (Marquez-
Klaka et al. 2007, 2009). How could the region Thr186-
Phe195 interact with this proposed binding pocket? Recent
mutagenesis studies on the P2X7 receptor showed that His62
(two residues before the conserved lysine doublet equivalent
to Lys68 and Lys70 in the P2X1 receptor) and Asp197
(equivalent to Ser194 in the P2X1 receptor) contribute to
zinc and copper inhibition (Liu et al. 2007). This raises the
possibility that these residues could be in close proximity as
demonstrated for two histidine residues in adjacent subunits
of the P2X2 receptor that are essential for zinc potentiation
(Nagaya et al. 2005). Such an interaction would bring the
region Thr186-Phe195 close to the predicted ATP binding
site, provide a contribution of Lys190 to the ATP binding
pocket, and a role of Phe195 in gating/ionic permeation
(Fig. 7).
In summary analysis of mutants in the region Glu191-
Val200 has highlighted the contribution of a beta sheet region
of the P2X1 receptor to ATP action and provided an updated
model of the agonist binding site. The work also shows that
the residue Phe195 in the middle of the extracellular loop
plays a role in channel gating and suggests that there are
widespread changes in the conformation of the receptor on
activation.
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